Skip to main content Back to Top


Mineral Oil and Petrolatum Ophthalmic Ointment

Products Affected - Description

    • Refresh Lacri-Lube, Allergan, 42.5%/56.8%, 3.5 g NDC 00023-0312-04
    • Refresh Lacri-Lube PM, Allergan, 42.5%/56.8%, 7 g NDC 00023-0312-07 - discontinued
    • Refresh PM, Allergan, 42.5%/57.3%, 3.5 g NDC 00023-0240-04

Reason for the Shortage

    • Allergan did not provide a reason for the shortage. The Lacri-Lube SOP 7 gram tubes have been discontinued.
    • Bausch Health has Soothe Night Time ointment available.
    • Major has Lubrifresh PM available.
    • Alcon states the shortage was due to manufacturing issues and increased demand.
    • Perrigo discontinued Puralube ointment products in early-2019.
    • Rugby discontinued Artificial Tears 3.5 gram tubes in January 2019.

Available Products

    • Genteal Tears Severe Nighttime Ointment, Alcon Labs, 3%/94%, 3.5 g Product 00065-0518-01
    • Lubrifresh PM, Major, 15%/83%, 3.5 g NDC 00904-6488-38
    • Soothe Night Time, Bausch Health, 20%/80%, 3.5 g NDC 10119-0223-99
    • Systane Nighttime Ointment, Alcon Labs, 3%/94%, 3.5 g Product 00065-0509-35

Estimated Resupply Dates

    • Allergan has Refresh PM and Refresh Lacrilube in 3.5 gram tubes on back order and the company estimates a release date of early-April 2020 for Refresh PM and late-March 2020 for Refresh LacriLube.


Updated March 24, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 6, 2018 by Anthony Trovato, PharmD, BCPS. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.